This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Don't Read Too Much Into the Downers of the Dow

NEW YORK (TheStreet) -Today's market ended with the Dow Jones Industrial Average down 44 points while the S&P was in fact up 0.28%. Why the divergence? Key Dow components reported quarters that were seen as disappointing, but ultimately, as I highlight below, these names are still well positioned and we still see an underlying healthy market. 

The downers of the Dow?

Verizon (VZ - Get Report): While the company reported a solid quarter (ie solid wireless results and improving wireline margins), Verizon didn't give fulsome 2014 guidance--largely due to pending Vodafone deal. Yes, there is more spending coming for the company: Verizon guided for full-year 2014 capex of $16.5 billion to $17.0 billion, about 2% higher than consensus expectations (beneficiaries include names like Ciena (CIEN - Get Report) and Juniper (JNPR) along with the tower companies like SBA Communications (SBAC) and American Tower (AMT)). And yes, the company will be issuing 1.2 billion new shares related to the Vodafone deal, expected to close in a month. But that will be temporary pressure and the company still has a solid dividend with growth.

Travelers (TRV - Get Report): The insurance giant reported a fourth quarter beat, but the stock sold off as investors worried about pricing slowing, a question-mark that has been plaguing the full property & casualty (P&C) group. A still well-positioned name in the group is American International Group (AIG), which remains a turnaround name driven by P&C driven operating recovery.

Johnson & Johnson (JNJ - Get Report): The quarter was solid and 2014 guidance was conservative and achievable. This is a great name in the pharma group because it is defensive but also has embraced more growth of late with pharma product launches (recent launches include Zytiga and Xarelto) with more to come (Imbruvica, Invokana), consumer products issues in the rearview, and improving utilization trends in medical devices. That 3% dividend yield is pretty compelling as well.

The bottom line: All three of the supposed disappointments in the Dow today remain well positioned. And we still saw underlying market strength in the broader averages. Still early in earnings season, we need to see more from companies before we jump to any conclusions.

Must Read: J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech

Of course, one Dow component that reported after the bell remains a troubled spot: International Business Machines Corp (IBM - Get Report). The financial engineering to get to the $20 EPS target in 2015 still shows no signs of real growth.. and this operational miss is keeping investors at bay.

--Written by Nicole Urken in New York.

>Contact by Email.


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Nicole's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs